Antibody-Drug Conjugates Are ‘Changing Outcomes’ in HR+ HER2– Breast Cancer

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Sara M. Tolaney, MD, MPH, spoke with CancerNetwork^® about how findings from the phase 3 TROPiCS-02 study (NCT03901339) highlight the ability of sacituzumab govitecan-hziy (Trodelvy) to improve patient outcomes over chemotherapy among those with hormone receptor–positive, HER2-negative metastatic breast cancer.

Tolaney, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, discussed the low response rates and short duration of disease control associated with single agent chemotherapy in the aforementioned population.

In the TROPiCs-02 study, investigators reported a median overall survival (OS) of 14.5 months with sacituzumab vs 11.2 months with chemotherapy of physician’s choice (Hazard ratio, 0.79; 95% CI, 0.65-0.95; P = .0133).Additionally, the 12-month, 18-month, and 24-month OS rates among patients receiving sacituzumab vs those receiving chemotherapy were 60.9% (95% CI, 54.8%-66.4%) vs47.1% (95% CI, 41.0%-53.0%), 39.2% (95% CI, 33.4%-45.0%) vs 31.7% (95% CI, 26.2%-37.4%), and 25.6% (95% CI, 20.4%-31.2%) vs 21.1% (95% CI, 16.3%-26.3%), respectively.

Transcript:

It's really exciting to see that antibody-drug conjugates are changing outcomes for patients. We've been so used to seeing single agent chemotherapy being given sequentially in this pretreated setting, and, unfortunately, it has been associated with low response rates and short duration of disease control.

These data looking at sacituzumab can tell us that we do have new agents that do better than standard chemotherapy and are really improving outcomes for our patients.

Reference

Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol. 2023;41(suppl 16):1003. doi:10.1200/JCO.2023.41.16_suppl.1003